Next-generation Sequencing (NGS) Market Size, Share & Trends Analysis By Product, By Technology, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global Next-generation Sequencing (NGS) Market is projected to be worth USD 43.97 billion by 2030.
According to SPER Market Research, the Next-generation Sequencing (NGS) Market is estimated to reach USD 43.97 billion by 2030 with a CAGR of 17.5%.
The rising occurrence of cancer, advancements in NGS platforms, diminishing costs of genome sequencing, and growing applications of NGS in cancer research are the key factors that impel the escalation of the market.
Impact of COVID-19 on the Next-generation Sequencing (NGS) Market
Start-ups in the NGS market, and pharmaceutical and biopharmaceutical companies have contributed to the research of vaccines, test kits, and treatments. The high degree of research & development of the companies for developing novel drugs to treat the infection. COVID-19 has a positive impact on the Next-generation Sequencing (NGS) Market.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product, By Technology, By Application, By End-Users, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered 10x Genomics, Agilent Technologies, Beckman Coulter, Becton, BGI Group, Dickinson, and Company, Eurofins, F. Hoffmann-La Roche AG, GENEWIZ, Hamilton Company, Illumina, Lucigen Corporation, Merck, MoBiTec GmbH, Molecular Biology Resources, Novogene Co., Ltd., NuGen Technologies, Oxford Nanopore Technologies, Promega, Psomagen, Pacific Biosciences, PerkinElmer, QIAGEN, Randox, Roche, Takara Bio, Thermo Fisher, Zymo Research Corporation
Driver: advancement in NGS platform
Advancements in NGS platforms, Declining costs of genome sequencing, improving regulatory and reimbursement scenarios for NGS-based diagnostic tests, Growing incidence of cancer, and increasing applications of next-generation sequencing in cancer research; are the key drivers for the escalation of the market.
Restraints: End-user budget constraints in developing countries
The developing counties’ research & development mainly depends upon external funding. Budget constraints in developing countries are the main cause to resist the expansion of the market.
Opportunity: Government & private support for large-scale sequencing
Applications of NGS in personalized medicine, molecular diagnostics, and government hold for huge level sequencing, create vast opportunities for the players in this market.
Challenges:
Interpretation of complex data from NGS platforms, Ethical issues, and Introduction of alternative technologies; are the challenges to the market.
Global Next-generation Sequencing (NGS) Market, By Product:
Based on the Product, Global Next-generation Sequencing (NGS) Market is segmented as; NGS Consumables, Sequencing Services (Exome & Targeted Resequencing & Custom Panels, Whole-Genome Sequencing & De Novo Sequencing, RNA Sequencing, Other Sequencing Services), Presequencing Products & Services (Library Preparation & Target Enrichment, Quality Control), NGS Platforms (Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, Pacific Biosciences, Other Platforms), Bioinformatics(Data Analysis Services, NGS Data Analysis Software & Workbenches, NGS Storage, Management, & Cloud Computing Solutions), Services for NGS Platforms.
Global Next-generation Sequencing (NGS) Market, By Technology:
Based on the Technology, Global Next-generation Sequencing (NGS) Market is segmented as; ION Semiconductor Sequencing, Nanopore Sequencing, Sequencing by Synthesis, Single-Molecule Real-Time Sequencing, and Other Technologies.
Global Next-generation Sequencing (NGS) Market, By Application:
Based on the Application, Global Next-generation Sequencing (NGS) Market is segmented into; Diagnostics (Cancer Diagnostics, Infectious Disease Diagnostics, Reproductive Health Diagnostics, Other Diagnostic Applications), Drug Discovery, Agricultural & Animal Research, and Other Applications.
Global Next-generation Sequencing (NGS) Market, By End User:
Based on the End-User, Global Next-generation Sequencing (NGS) Market is segmented as; Academic Institutes & Research Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Other End Users.
Global Next-generation Sequencing (NGS) Market, By Region:
North America dominates the major shares of the Next-generation Sequencing (NGS) Market; it is due to the growing applications of NGS in diagnostics, genomic research, and accessibility to research funding.
According to SPER Market Research, the Next-generation Sequencing (NGS) Market is estimated to reach USD 43.97 billion by 2030 with a CAGR of 17.5%.
The rising occurrence of cancer, advancements in NGS platforms, diminishing costs of genome sequencing, and growing applications of NGS in cancer research are the key factors that impel the escalation of the market.
Impact of COVID-19 on the Next-generation Sequencing (NGS) Market
Start-ups in the NGS market, and pharmaceutical and biopharmaceutical companies have contributed to the research of vaccines, test kits, and treatments. The high degree of research & development of the companies for developing novel drugs to treat the infection. COVID-19 has a positive impact on the Next-generation Sequencing (NGS) Market.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product, By Technology, By Application, By End-Users, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered 10x Genomics, Agilent Technologies, Beckman Coulter, Becton, BGI Group, Dickinson, and Company, Eurofins, F. Hoffmann-La Roche AG, GENEWIZ, Hamilton Company, Illumina, Lucigen Corporation, Merck, MoBiTec GmbH, Molecular Biology Resources, Novogene Co., Ltd., NuGen Technologies, Oxford Nanopore Technologies, Promega, Psomagen, Pacific Biosciences, PerkinElmer, QIAGEN, Randox, Roche, Takara Bio, Thermo Fisher, Zymo Research Corporation
Driver: advancement in NGS platform
Advancements in NGS platforms, Declining costs of genome sequencing, improving regulatory and reimbursement scenarios for NGS-based diagnostic tests, Growing incidence of cancer, and increasing applications of next-generation sequencing in cancer research; are the key drivers for the escalation of the market.
Restraints: End-user budget constraints in developing countries
The developing counties’ research & development mainly depends upon external funding. Budget constraints in developing countries are the main cause to resist the expansion of the market.
Opportunity: Government & private support for large-scale sequencing
Applications of NGS in personalized medicine, molecular diagnostics, and government hold for huge level sequencing, create vast opportunities for the players in this market.
Challenges:
Interpretation of complex data from NGS platforms, Ethical issues, and Introduction of alternative technologies; are the challenges to the market.
Global Next-generation Sequencing (NGS) Market, By Product:
Based on the Product, Global Next-generation Sequencing (NGS) Market is segmented as; NGS Consumables, Sequencing Services (Exome & Targeted Resequencing & Custom Panels, Whole-Genome Sequencing & De Novo Sequencing, RNA Sequencing, Other Sequencing Services), Presequencing Products & Services (Library Preparation & Target Enrichment, Quality Control), NGS Platforms (Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, Pacific Biosciences, Other Platforms), Bioinformatics(Data Analysis Services, NGS Data Analysis Software & Workbenches, NGS Storage, Management, & Cloud Computing Solutions), Services for NGS Platforms.
Global Next-generation Sequencing (NGS) Market, By Technology:
Based on the Technology, Global Next-generation Sequencing (NGS) Market is segmented as; ION Semiconductor Sequencing, Nanopore Sequencing, Sequencing by Synthesis, Single-Molecule Real-Time Sequencing, and Other Technologies.
Global Next-generation Sequencing (NGS) Market, By Application:
Based on the Application, Global Next-generation Sequencing (NGS) Market is segmented into; Diagnostics (Cancer Diagnostics, Infectious Disease Diagnostics, Reproductive Health Diagnostics, Other Diagnostic Applications), Drug Discovery, Agricultural & Animal Research, and Other Applications.
Global Next-generation Sequencing (NGS) Market, By End User:
Based on the End-User, Global Next-generation Sequencing (NGS) Market is segmented as; Academic Institutes & Research Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Other End Users.
Global Next-generation Sequencing (NGS) Market, By Region:
North America dominates the major shares of the Next-generation Sequencing (NGS) Market; it is due to the growing applications of NGS in diagnostics, genomic research, and accessibility to research funding.
1. INTRODUCTION
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Next-generation Sequencing (NGS) Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
6.1. NGS Consumables
6.2. Sequencing Services
6.2.1. Exome & Targeted Resequencing & Custom Panels
6.2.2. Whole-Genome Sequencing & De Novo Sequencing
6.2.3. RNA Sequencing
6.2.4. Other Sequencing Services
6.3. Presequencing Products & Services
6.3.1 Library Preparation & Target Enrichment
6.3.2 Quality Control
6.4. NGS Platforms
6.4.1 Illumina
6.4.1.1. Novaseq Systems
6.4.1.2. Nextseq Systems
6.4.1.3. Miseq Systems
6.4.1.4. Miniseq Systems
6.4.1.5. iSeq Systems
6.4.2 Thermo Fisher Scientific
6.4.2.1. ION PGM Systems
6.4.2.2. ION Proton Systems
6.4.2.3. ION Genestudio Systems
6.4.2.4. Ion Torrent Genexus Systems
6.4.3 Oxford Nanopore Technologies
6.4.4 Pacific Biosciences
6.4.5 Other Platforms
6.5. Bioinformatics
6.5.1. Data Analysis Services
6.5.2. NGS Data Analysis Software & Workbenches
6.5.3. NGS Storage, Management, & Cloud Computing Solutions
6.6. Services for NGS Platforms
7. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2019-2030 (USD MILLION)
7.1. ION Semiconductor Sequencing
7.2. Nanopore Sequencing
7.3. Other Technologies
7.4. Sequencing by Synthesis
7.5. Single-Molecule Real-Time Sequencing
8. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2019-2030 (USD MILLION)
8.1. Diagnostics
8.1.1 Cancer Diagnostics
8.1.2 Infectious Disease Diagnostics
8.1.3 Reproductive Health Diagnostics
8.1.4 Other Diagnostic Applications
8.2. Drug Discovery
8.3. Agricultural & Animal Research
8.4. Other Applications
9. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2019-2030 (USD MILLION)
9.1. Academic Institutes & Research Centers
9.2. Hospitals & Clinics
9.3. Other End Users
9.4. Pharmaceutical & Biotechnology Companies
10. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2019-2030 (USD MILLION)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. Europe
10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. COMPANY PROFILES
11.1. 11x Genomics
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Agilent
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Beckman Coulter
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Becton
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. BGI Group
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Eurofins
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. F. Hoffmann-La Roche AG
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. GENEWIZ
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Illumina
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. LGC Biosearch Technologies
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Lucigen Corporation
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Molecular Biology Resources
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. NuGen Technologies
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.13.5.
11.14. NZYTech
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. Promega, Inc.
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. QIAGEN
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. Takara Bio
11.17.1. Company details
11.17.2. Financial outlook
11.17.3. Product summary
11.17.4. Recent developments
11.18. Thermo Fisher
11.18.1. Company details
11.18.2. Financial outlook
11.18.3. Product summary
11.18.4. Recent developments
11.19. Zymo Research Corporation
11.19.1. Company details
11.19.2. Financial outlook
11.19.3. Product summary
11.19.4. Recent developments
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Next-generation Sequencing (NGS) Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
6.1. NGS Consumables
6.2. Sequencing Services
6.2.1. Exome & Targeted Resequencing & Custom Panels
6.2.2. Whole-Genome Sequencing & De Novo Sequencing
6.2.3. RNA Sequencing
6.2.4. Other Sequencing Services
6.3. Presequencing Products & Services
6.3.1 Library Preparation & Target Enrichment
6.3.2 Quality Control
6.4. NGS Platforms
6.4.1 Illumina
6.4.1.1. Novaseq Systems
6.4.1.2. Nextseq Systems
6.4.1.3. Miseq Systems
6.4.1.4. Miniseq Systems
6.4.1.5. iSeq Systems
6.4.2 Thermo Fisher Scientific
6.4.2.1. ION PGM Systems
6.4.2.2. ION Proton Systems
6.4.2.3. ION Genestudio Systems
6.4.2.4. Ion Torrent Genexus Systems
6.4.3 Oxford Nanopore Technologies
6.4.4 Pacific Biosciences
6.4.5 Other Platforms
6.5. Bioinformatics
6.5.1. Data Analysis Services
6.5.2. NGS Data Analysis Software & Workbenches
6.5.3. NGS Storage, Management, & Cloud Computing Solutions
6.6. Services for NGS Platforms
7. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2019-2030 (USD MILLION)
7.1. ION Semiconductor Sequencing
7.2. Nanopore Sequencing
7.3. Other Technologies
7.4. Sequencing by Synthesis
7.5. Single-Molecule Real-Time Sequencing
8. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2019-2030 (USD MILLION)
8.1. Diagnostics
8.1.1 Cancer Diagnostics
8.1.2 Infectious Disease Diagnostics
8.1.3 Reproductive Health Diagnostics
8.1.4 Other Diagnostic Applications
8.2. Drug Discovery
8.3. Agricultural & Animal Research
8.4. Other Applications
9. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2019-2030 (USD MILLION)
9.1. Academic Institutes & Research Centers
9.2. Hospitals & Clinics
9.3. Other End Users
9.4. Pharmaceutical & Biotechnology Companies
10. NEXT-GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2019-2030 (USD MILLION)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. Europe
10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. COMPANY PROFILES
11.1. 11x Genomics
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Agilent
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Beckman Coulter
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Becton
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. BGI Group
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Eurofins
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. F. Hoffmann-La Roche AG
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. GENEWIZ
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Illumina
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. LGC Biosearch Technologies
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Lucigen Corporation
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Molecular Biology Resources
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. NuGen Technologies
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.13.5.
11.14. NZYTech
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. Promega, Inc.
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. QIAGEN
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. Takara Bio
11.17.1. Company details
11.17.2. Financial outlook
11.17.3. Product summary
11.17.4. Recent developments
11.18. Thermo Fisher
11.18.1. Company details
11.18.2. Financial outlook
11.18.3. Product summary
11.18.4. Recent developments
11.19. Zymo Research Corporation
11.19.1. Company details
11.19.2. Financial outlook
11.19.3. Product summary
11.19.4. Recent developments
